menu
    • menu
    [{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"HT-003","moa":"TLR2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Weill Cornell Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Weill Cornell Medicine \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Weill Cornell Medicine \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"Akelos","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"AKE-1018","moa":"HCN1 channel","graph1":"Neurology","graph2":"Preclinical","graph3":"Weill Cornell Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Weill Cornell Medicine \/ Weill Cornell Medicin","highestDevelopmentStatusID":"4","companyTruncated":"Weill Cornell Medicine \/ Weill Cornell Medicin"},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"AffyImmune Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AIC100","moa":"ICAM-1","graph1":"Oncology","graph2":"Phase I","graph3":"Weill Cornell Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Weill Cornell Medicine \/ Weill Medical College of Cornell University","highestDevelopmentStatusID":"6","companyTruncated":"Weill Cornell Medicine \/ Weill Medical College of Cornell University"}]

    Find Clinical Drug Pipeline Developments & Deals by Weill Cornell Medicine

    Menu

    Weill Cornell Medicine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Weill Cornell Medicine

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Weill Cornell Medicine

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AIC100

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : AffyImmune Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer

                            Details : The FDA's Fast Track designation is designed for AIC100 facilitate development and expedite review of drug candidates to treat serious conditions and address an unmet medical need.

                            Brand Name : AIC100

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 17, 2021

                            Lead Product(s) : AIC100

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : AffyImmune Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Weill Cornell Medicine

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Weill Cornell Medicine

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AKE-1018

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Akelos

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Akelos Inc.'s Lead Compound Achieves Preclinical Safety Milestone

                            Details : Akelos's oral lead compound AKE-1018, at 10-times the lowest effective antihyperalgesic dose tested, does not affect heart rate, blood pressure, motor strength/coordination, is non-sedating, and lacks the potential for abuse.

                            Brand Name : AKE-1018

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            March 04, 2021

                            Lead Product(s) : AKE-1018

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Akelos

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Weill Cornell Medicine

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Weill Cornell Medicine

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HT-003

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Hoth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Hoth Therapeutics Expands Research Collaboration with Weill Cornell Medicine to Continue Advancement of HT-003...

                            Details : The 1-year agreement extension is based on positive results generated from the prior research agreement that support a therapeutic effect of HT-003 in key signaling pathways contributing to the development of acne.

                            Brand Name : HT-003

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 28, 2021

                            Lead Product(s) : HT-003

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Hoth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth